In December 2020, the FDA granted emergency use authorization for two COVID-19 vaccines. And although there were more than 20 other vaccine candidates undergoing phase 2 or 3 testing as of January 2021, there is more work to be done. Precision’s Marlon Graf and Rifat Tuly identify two components that are required for continued success with COVID-19 vaccine policies, and discuss ways to address them to ensure that the discovery and development of new vaccines for COVID-19 and future pandemics can be sustained in the future.

Read the full article here